Biolinerx Ltd. (BLRX)

Trade BLRX now with
12/16/2020 6:03:36 AM BioLineRx Announces Results From Triple Combination Arm Of COMBAT/KEYNOTE-202 Clinical Study
11/23/2020 7:15:34 AM BioLineRx Q3 Net Loss $4.6 Mln Vs Loss $3.9 Mln Last Year
11/18/2020 7:17:38 AM BioLineRx Initiates Phase 1b Trial In Patients With ARDS Secondary To COVID-19 And Other Respiratory Viral Infections
10/30/2020 7:23:18 AM BioLineRx Announces Positive Results From Interim Analysis Of GENESIS Phase 3 Trial Of Motixafortide
10/29/2020 8:52:44 AM BioLineRx Begins Phase 2 Clinical Trial In First-Line Metastatic Pancreatic Cancer
8/19/2020 7:03:08 AM BioLineRx Achieves Enrollment Target In Phase 3 GENESIS Trial For Planned Interim Analysis
8/6/2020 7:28:10 AM BioLineRx Q2 Net Loss $6.8 Mln Vs Net Loss $5.5 Mln Last Year
6/1/2020 8:01:13 AM BioLineRx Plans $4.39 Mln Registered Direct Offering
5/27/2020 7:04:13 AM BioLineRx Publishes Data From COMBAT/KEYNOTE-202 Clinical Trial In Nature Medicine
5/26/2020 8:43:42 AM BioLineRx Prices Sale Of 5.14 Mln ADS At $1.75 Per ADS
5/20/2020 7:15:29 AM BioLineRx Q1 Loss Per Share $0.05 Vs Loss $0.04 Last Year
3/12/2020 7:12:03 AM BioLineRx FY Net Loss $25.5 Mln Vs Loss Of $23.0 Mln Last Year
2/27/2020 8:17:53 AM BioLineRx Announces Notice Of Allowance From USPTO For Patent Covering Motixafortide In Combination With Anti-PD-1
1/14/2020 7:05:42 AM BioLineRx Receives Orphan Drug Designation For Motixafortide For Pancreatic Cancer In Europe
12/13/2019 7:08:15 AM BioLineRx Updates Data From Triple Combination Arm Of Ongoing Phase 2a COMBAT/KEYNOTE-202 Study